Skip to Main Content

Most Cited Articles

Explore European Heart Journal (EHJ) articles that are making a big impact! The EHJ editors invite you to read the top 15 most cited articles published within the past 12 months. This page is automated to reflect current readership, so bookmark this page and check back often to stay up-to-date with recent changes.

2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS)
Christiaan Vrints and others
European Heart Journal, Volume 45, Issue 36, 21 September 2024, Pages 3415–3537, https://doi.org/10.1093/eurheartj/ehae177
Guidelines evaluate and summarize available evidence with the aim of assisting health professionals in proposing the best diagnostic or therapeutic approach for an individual patient with a given condition. Guidelines are intended for use by health professionals, and the European Society of Cardiology (ESC) makes its ...
2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO)
Isabelle C Van Gelder and others
European Heart Journal, Volume 45, Issue 36, 21 September 2024, Pages 3314–3414, https://doi.org/10.1093/eurheartj/ehae176
Guidelines evaluate and summarize available evidence with the aim of assisting health professionals in proposing the best diagnostic or therapeutic approach for an individual patient with a given condition. Guidelines are intended for use by health professionals and the European Society of Cardiology (ESC) makes its ...
2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO)
John William McEvoy and others
European Heart Journal, Volume 45, Issue 38, 7 October 2024, Pages 3912–4018, https://doi.org/10.1093/eurheartj/ehae178
Guidelines evaluate and summarize available evidence with the aim of assisting health professionals in proposing the best diagnostic or therapeutic approach for an individual patient with a given condition. Guidelines are intended for use by health professionals and the European Society of Cardiology (ESC) makes its ...
Lumican promotes calcific aortic valve disease through H3 histone lactylation
Yuming Huang and others
European Heart Journal, Volume 45, Issue 37, 1 October 2024, Pages 3871–3885, https://doi.org/10.1093/eurheartj/ehae407
Background and Aims Valve interstitial cells (VICs) undergo a transition to intermediate state cells before ultimately transforming into the osteogenic cell population, which is a pivotal cellular process in calcific aortic valve disease (CAVD). Herein, this study successfully delineated the stages of VIC osteogenic ...
Transcatheter aortic valve implantation in low-risk tricuspid or bicuspid aortic stenosis: the NOTION-2 trial
Troels Højsgaard Jørgensen and others
European Heart Journal, Volume 45, Issue 37, 1 October 2024, Pages 3804–3814, https://doi.org/10.1093/eurheartj/ehae331
Background and Aims Transcatheter aortic valve implantation (TAVI) has become the first choice to treat older patients with severe symptomatic aortic stenosis (AS). This study aimed to compare TAVI with surgery in low-risk patients ≤75 years of age, including both tricuspid and bicuspid AS. Methods The Nordic Aortic Valve ...
Obesity and cardiovascular disease: an ESC clinical consensus statement
Konstantinos C Koskinas and others
European Heart Journal, Volume 45, Issue 38, 7 October 2024, Pages 4063–4098, https://doi.org/10.1093/eurheartj/ehae508
The global prevalence of obesity has more than doubled over the past four decades, currently affecting more than a billion individuals. Beyond its recognition as a high-risk condition that is causally linked to many chronic illnesses, obesity has been declared a disease per se that results in impaired quality of life and ...
European Society of Cardiology: the 2023 Atlas of Cardiovascular Disease Statistics
Adam Timmis and others
European Heart Journal, Volume 45, Issue 38, 7 October 2024, Pages 4019–4062, https://doi.org/10.1093/eurheartj/ehae466
This report from the European Society of Cardiology (ESC) Atlas Project updates and expands upon the 2021 report in presenting cardiovascular disease (CVD) statistics for the ESC member countries. This paper examines inequalities in cardiovascular healthcare and outcomes in ESC member countries utilizing mortality and risk ...
Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials
Sanjiv J Shah and others
European Heart Journal, Volume 45, Issue 35, 14 September 2024, Pages 3254–3269, https://doi.org/10.1093/eurheartj/ehae322
Background and Aims In the STEP-HFpEF trial programme, treatment with semaglutide resulted in multiple beneficial effects in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). Efficacy may vary according to baseline diuretic use, and semaglutide treatment could modify diuretic dose. ...
Myocardial reperfusion injury exacerbation due to ALDH2 deficiency is mediated by neutrophil extracellular traps and prevented by leukotriene C4 inhibition
Kun Yang and others
European Heart Journal, Volume 45, Issue 18, 7 May 2024, Pages 1662–1680, https://doi.org/10.1093/eurheartj/ehae205
Background and Aims The Glu504Lys polymorphism in the aldehyde dehydrogenase 2 ( ALDH2 ) gene is closely associated with myocardial ischaemia/reperfusion injury (I/RI). The effects of ALDH2 on neutrophil extracellular trap (NET) formation (i.e. NETosis) during I/RI remain unknown. This study aimed to investigate the role ...
Discordance among apoB, non–high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention
Allan D Sniderman and others
European Heart Journal, Volume 45, Issue 27, 14 July 2024, Pages 2410–2418, https://doi.org/10.1093/eurheartj/ehae258
Background and Aims Despite growing evidence that apolipoprotein B (apoB) is the most accurate marker of atherosclerotic cardiovascular disease (ASCVD) risk, its adoption in clinical practice has been low. This investigation sought to determine whether low-density lipoprotein cholesterol (LDL-C), non–high-density ...
Atrial fibrillation burden: a new outcome predictor and therapeutic target
Nina Becher and others
European Heart Journal, Volume 45, Issue 31, 14 August 2024, Pages 2824–2838, https://doi.org/10.1093/eurheartj/ehae373
Atrial fibrillation (AF), the most common sustained cardiac arrhythmia, is not a dichotomous disease trait. Technological innovations enable long-term rhythm monitoring in many patients and can estimate AF burden. These technologies are already used to detect and monitor AF. This review describes the relation between AF ...
Embolic strokes of undetermined source: a clinical consensus statement of the ESC Council on Stroke, the European Association of Cardiovascular Imaging and the European Heart Rhythm Association of the ESC
George Ntaios and others
European Heart Journal, Volume 45, Issue 19, 14 May 2024, Pages 1701–1715, https://doi.org/10.1093/eurheartj/ehae150
One in six ischaemic stroke patients has an embolic stroke of undetermined source (ESUS), defined as a stroke with unclear aetiology despite recommended diagnostic evaluation. The overall cardiovascular risk of ESUS is high and it is important to optimize strategies to prevent recurrent stroke and other cardiovascular ...
Artificial intelligence in cardiovascular medicine: clinical applications
Thomas F Lüscher and others
European Heart Journal, Volume 45, Issue 40, 21 October 2024, Pages 4291–4304, https://doi.org/10.1093/eurheartj/ehae465
Clinical medicine requires the integration of various forms of patient data including demographics, symptom characteristics, electrocardiogram findings, laboratory values, biomarker levels, and imaging studies. Decision-making on the optimal management should be based on a high probability that the envisaged treatment is ...
Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial
Stephan von Haehling and others
European Heart Journal, Volume 45, Issue 37, 1 October 2024, Pages 3789–3800, https://doi.org/10.1093/eurheartj/ehae479
Background and Aims Evidence is lacking that correcting iron deficiency (ID) has clinically important benefits for patients with heart failure with preserved ejection fraction (HFpEF). Methods FAIR-HFpEF was a multicentre, randomized, double-blind trial designed to compare intravenous ferric carboxymaltose (FCM) with ...
A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers
Richard T Carrick and others
European Heart Journal, Volume 45, Issue 32, 21 August 2024, Pages 2968–2979, https://doi.org/10.1093/eurheartj/ehae409
Background and Aims Pathogenic desmoplakin ( DSP ) gene variants are associated with the development of a distinct form of arrhythmogenic cardiomyopathy known as DSP cardiomyopathy. Patients harbouring these variants are at high risk for sustained ventricular arrhythmia (VA), but existing tools for individualized ...
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close